Overview

The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives

Status:
Withdrawn
Trial end date:
2015-04-01
Target enrollment:
0
Participant gender:
Female
Summary
The purpose of this study is to determine whether vilazodone is more effective than citalopram for the treatment of anxious depression. We will use neuroimaging to see whether there are changes in the brains of patients receiving the drug vilazodone that are different from those of citalopram. These changes may show that vilazodone affects the brain differently than most other kinds of standard antidepressant medications.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
Citalopram
Dexetimide
Serotonin
Vilazodone Hydrochloride
Criteria
Inclusion Criteria:

- Female, aged 18-50 years.

- Meets DSM-IV criteria for unipolar major depression.

- MADRS score > 20.

- Subject exhibits clinically significant anxiety and HAM-A score > 15.

- Capable of providing informed consent.

- Has an established residence and phone.

Exclusion Criteria:

- A clinically significant medical condition which could impact the response of the
individual to antidepressant treatment (e.g. diabetes, cancer, lupus or other
autoimmune illness). Stably treated hypothyroidism (TSH < 2) will be permitted.

- Beta blockers, antidepressants, antipsychotics, lithium, antiepileptic medications,
steroids (oral and inhaled), chronic use of nonsteroidal antinflamatory medications
(infrequent sporadic use permitted), or other medications with the potential to
interfere with the antidepressant effects of Vilazodone.

- Pregnancy.

- In women of childbearing potential an unwillingness to use reliable methods to prevent
pregnancy.

- History of manic or psychotic symptoms.

- History of seizure or epilepsy.

- History of alcohol or drug dependence and active use of substances in the past month.

- Active alcohol or drug abuse.

- Ingestion of 4 or more caffeinated beverages a day, on average.